Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
Rhea-AI Summary
Dyadic (Nasdaq: DYAI) will report Q1 2026 financial results and host a corporate update conference call on Wednesday, May 13, 2026 at 5:00 p.m. ET. The live dial-in and webcast details are provided below; an archived replay will be available within 24 hours on the company's Investor Relations website.
Dial-in numbers: Toll Free +1-877-407-9219 / +1-412-652-1274. Conference ID: 13759380. Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qVNgtGJ6. Submit Q&A questions in advance to jlavalley@dyadic.com.
Positive
- None.
Negative
- None.
News Market Reaction – DYAI
In the Apr 30 session, DYAI gained 3.54%, reflecting a moderate positive market reaction. Argus tracked a trough of -17.6% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was exceptionally heavy at 6.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 11 | Earnings call date | Neutral | -4.6% | Company scheduled full-year 2025 earnings release and conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last earnings-date conference call announcement saw a -4.57% move, suggesting such scheduling news has previously coincided with modest downside.
Over recent months, Dyadic has combined commercial expansion with increasing investor communications. A prior announcement on Mar 11, 2026 set the schedule for 2025 full-year results and an earnings call, which was followed by a -4.57% move. Together with subsequent filings highlighting weaker 2025 results and Nasdaq compliance issues, today’s Q1 2026 call scheduling continues a pattern of regular financial updates amid operational and listing challenges.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the quarter ended March 31, 2026 and host a corporate update conference call on Wednesday, May 13, 2026.
Conference Call Information
Date: Wednesday, May 13, 2026
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-9219 / +1 412-652-1274
Conference ID: 13759380
Webcast Link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qVNgtGJ6 An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email jlavalley@dyadic.com prior to the conference call.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs. For more information, please visit www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at www.dyadic.com.
Contact:
Ping Rawson
Dyadic Applied BioSolutions
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
